Edison’s Vatiquinone receives FDA orphan drug status for Leigh syndrome
Inherited mitochondrial disease treatment specialists Edison Pharmaceuticals has received orphan drug designation from the US Food and Drug Administration (FDA) for its vatiquinone to treat Leigh syndrome.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news